News from resverlogix corp A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

( OTC-BB:XPWR)

Aug 04, 2015, 07:30 ET

International Clinical Steering Committee Announced for Resverlogix's Phase 3 BETonMACE Clinical Trial with RVX-208 "apabetalone"

Professor Kausik Ray to Chair Clinical Steering Committee for Landmark Epigenetic BET Inhibition Trial CALGARY, Aug. 4, 2015 /PRNewswire/...

Jul 22, 2015, 05:31 ET

Resverlogix cierra una financiación privada de 50 millones de dólares con Hepalink y Eastern Capital

- Símbolo de cotización TSX: RVX Resverlogix Corp. ("Resverlogix") (TSX:RVX) anunció hoy que ha cerrado su financiación...

Jul 21, 2015, 09:00 ET

Resverlogix Closes $50 Million Private Placement With Hepalink and Eastern Capital

TSX Exchange Symbol: RVX CALGARY, July 21, 2015 /PRNewswire/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced today that it has closed the...

Jul 08, 2015, 07:00 ET

Resverlogix Closes License Agreement and Enters Into Definitive Stock Purchase Agreement With Hepalink

TSX Exchange Symbol: RVX CALGARY, July 8, 2015 /PRNewswire/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced today that it has closed...

Jul 08, 2015, 07:00 ET

Resverlogix entra en un acuerdo de compra de stock definitivo con Hepalink

- Resverlogix cierra un acuerdo de licencia y entra en un acuerdo de compra de stock definitivo con Hepalink    Símbolo de la...

Jun 30, 2015, 17:39 ET

Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement

TSX Exchange Symbol: RVX CALGARY, June 30, 2015 /PRNewswire/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced today that holders...

Jun 22, 2015, 10:40 ET

Resverlogix mantiene oficialmente la categoría de fase 3 con la Autoridad Normativa Europea

Símbolo de cotización TSX: RVX Resverlogix Corp. (TSX: RVX) anunció hoy que tras las recientes reuniones celebradas con varios...

Jun 22, 2015, 07:30 ET

Resverlogix Officially Attains Phase 3 Status with a European Regulatory Authority

TSX Exchange Symbol: RVX CALGARY, June 22, 2015 /PRNewswire/ - Resverlogix Corp. (TSX: RVX) today announced that following recent meetings...

Jun 17, 2015, 07:30 ET

Resverlogix to Present at the 2015 Bio International Convention

TSX Exchange Symbol: RVX CALGARY and PHILADELPHIA, June 17, 2015 /PRNewswire/ - Resverlogix Corp. (TSX: RVX) (the "Company") today announced...

Jun 08, 2015, 11:35 ET

Resverlogix Reports on the Beneficial Effects of RVX-208 on Glucose Metabolism in Prediabetes Mellitus at the American Diabetes Association's (ADA) Scientific Sessions in Boston, MA

TSX Exchange Symbol: RVX CALGARY, June 8, 2015 /PRNewswire/ - Resverlogix Corp. (TSX: RVX) today announced that findings of a study performed by...

Jun 01, 2015, 08:26 ET

Resverlogix presenta sus nuevos datos

- Resverlogix presenta sus nuevos datos en el 52 congreso anual de la European Renal Association - European Dialysis & Transplant...

Jun 01, 2015, 07:30 ET

Resverlogix Presents New Data at 52nd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA)

RVX-208, the first selective bromodomain extra-terminal (BET) protein inhibitor, significantly reduces alkaline phosphatase (ALP) levels in...

Apr 28, 2015, 07:42 ET

Resverlogix y Shenzhen Hepalink Pharmaceutical Co., Ltd. anuncian un acuerdo de combinación de licencia y valores

- Resverlogix y Shenzhen Hepalink Pharmaceutical Co., Ltd., con sede en China, anuncian un acuerdo de combinación de licencia y...

Apr 27, 2015, 07:00 ET

Resverlogix and China-based Shenzhen Hepalink Pharmaceutical Co., Ltd. Announce a Combination Licensing and Equity Arrangement

The deal structure involves CAD$50 million in equity investments, and future China sales milestones and licensing royalties that could represent in...

Apr 07, 2015, 07:30 ET

Resverlogix Receives Two Patents for RVX-208 in China

CALGARY, April 7, 2015 /PRNewswire/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) announces that it has received two China...

Apr 07, 2015, 07:30 ET

Resverlogix recibe dos patentes para RVX-208 en China

Resverlogix Corp. ("Resverlogix" o "la compañía") (TSX: RVX) anunció que ha recibido dos aprobaciones de patente en China que...

Mar 16, 2015, 13:30 ET

Resverlogix Presents at the Prestigious American College of Cardiology 64th Annual Scientific Session & Expo (ACC.15)

RVX-208 the first selective bromodomain extra-terminal (BET) protein inhibitor being developed for patients with high residual risks of...

Mar 04, 2015, 09:00 ET

Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program

Emerald Logic FACET software generates predictive models and identifies novel variables driving RVX-208 drug efficacy, safety and reduced MACE...

Jan 14, 2015, 20:00 ET

Resverlogix Presents at Biotech Showcase During JP Morgan Week

SAN FRANCISCO, CA, Jan. 14, 2015 /PRNewswire/ - Resverlogix Corp. (TSX:RVX) (the "Company") today announced that Donald McCaffrey, president and...

Nov 03, 2014, 17:05 ET

Resverlogix Names Michael Sweeney, M.D., as Senior Vice President of Clinical Development

CALGARY, Nov. 3, 2014  /PRNewswire/ -  Resverlogix Corp. (TSX:RVX) today announced the appointment of Michael T. Sweeney, M.D., as...